COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Jumia Releases Preliminary KPIs For The Two Months Ended November 30, 2024; Announces Successful Black Friday Event
Jumia Technologies AG announces preliminary unaudited results of selected KPIs for the two months ended November 30, 2024, with Orders totaling 4.3 million, up 18% year-over-year, and Physical Goods Orders growing 17% -
COMMUNIQUÉ DE PRESSE
Gungnir Adds 92 Square Kilometres to Its Knaften-Hemberget Gold Line Property Package in Sweden
Gungnir Resources Inc. announces significant expansion of Knaften-Hemberget gold property in Sweden, adding 9,216 hectares. The project explores for gold deposits along The Gold Line structural trend -
-
-
COMMUNIQUÉ DE PRESSE
TRU Reports High Grade Gold in Rock Samples recovered from the Golden Rose Project
TRU Precious Metals Corp. reports high-grade gold assays from rock sampling at Golden Rose Project in Central Newfoundland. Sampling along Mark's Pond to Rich House exploration fairway reveals grades up to 1,361.3 g/t Au, with visible gold in 12 samples -
COMMUNIQUÉ DE PRESSE
Electric Royalties Provides Progress Updates on Its Graphite, Vanadium, Lithium, Manganese, Copper, Cobalt and Nickel Royalties
Electric Royalties Ltd. provides an update on its royalty portfolio, including progress on various projects and company advancements. Exciting exploration updates and partnerships enhance future cash flow potential -
-
COMMUNIQUÉ DE PRESSE
Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million
Quantum BioPharma announces a non-brokered private placement offering of convertible debenture units. Proceeds for business development and working capital -
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Galimedix Therapeutics initiates Phase 1 study with oral small molecule GAL-101, targeting neurodegenerative diseases. Study focuses on safety, tolerability, and pharmacokinetics for Alzheimer's, dry AMD, and glaucoma treatments
